A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between ...
A research team from IOCB Prague, working in collaboration with the University of Tübingen, Germany, and the Faculty of Science, Charles University, has developed a new type of contrast agent that can ...
MRI contrast agents, which are typically gadolinium-based, are used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue. This ...
Current PET/MRI imaging of healthy and damaged mouse kidneys using the dual contrast agent [18F][Gd(FL1)]. The imaging provides consistent signals from both PET and MRI. In healthy kidneys, the center ...
Medical imaging often facilitates the successful diagnosis and management of cancerous growths. In particular, magnetic resonance imaging (MRI) is extensively used, especially with contrast agents, ...
Magnetic resonance imaging (MRI) machines can clearly view non-bony parts of the body—soft tissue such as the brain, muscles and ligaments—as well as detect tumors, making it possible to diagnose many ...
New macrocyclic gadolinium-based contrast agent supports high-quality MRI while enabling a lower gadolinium dose when contrast-enhanced imaging is clinically appropriate1 MONTREAL, Aug. 5, 2026 ...
Hosted on MSN
The FDA approved a lower-dose contrast agent to cut patients’ exposure during MRI scans
Patients who need repeated MRI scans with contrast dye could soon receive a fraction of the gadolinium they currently get. The FDA approved gadoquatrane, a new gadolinium-based contrast agent designed ...
Bayer’s AMBELVIST® (gadoquatrane) becomes the lowest-dose macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) approved in the U.S., with a recommended dose of 0.01 mmol/kg actual body weight ...
An unexpected discovery surprised a scientist at the Max Planck Institute for Intelligent Systems in Stuttgart: Nanometer-sized diamond particles, which were intended for a completely different ...
CHALFONT ST GILES, England--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has today announced the completion of its Phase I clinical development program for a first-of-its-kind manganese-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results